Issue Date: September 3, 2007
NPIL Mulls Drug Discovery Spin-Off
Mumbai-based Nicholas Piramal India Ltd. is considering whether to turn its drug discovery research unit into a separate entity. Employing many Indian researchers recruited from the U.S., NPIL is one of India's most research-focused pharmaceutical companies. In July, the firm announced that it had an investigational new drug undergoing clinical trials at Harvard University's Dana-Farber Cancer Institute for treatment of multiple myeloma. One of the deadliest forms of cancers, myeloma is so far untreatable for most patients.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society